OGN · Organon & Co.
The latest filing no longer states the doubt (first flagged May 4, 2026).
View the 10-Q filed Jul 31, 2026Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA margin (Non-GAAP) non-GAAP | 28.4% | Q1 2026 | — |
| Non-GAAP Adjusted EBITDA non-GAAP | $383M | Q4 2025 | — |
| Non-GAAP Adjusted EBITDA margin non-GAAP | 25.4% | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OGN
this stock
Organon & Co.
|
$3.60B | +91.4% | -2.9% | 17.6 | 6.4% |
|
LLY
ELI LILLY & Co
|
$1.11T | +9.8% | +44.7% | 39.6 | 1.0% |
|
JNJ
Johnson & Johnson
|
$627.42B | +25.8% | +6.0% | 30.2 | 1.1% |
|
ABBV
AbbVie Inc.
|
$440.83B | +9.2% | +8.6% | 70.5 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$335.14B | +29.1% | +1.3% | 108.7 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OGN | +0.9% | +1.5% | +73.2% | +1.3% | +91.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.5% | -3.0% | +59.5% | -2.7% | +77.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.